Baird Maintains BIO-TECHNE Corp to Outperform with Price Target $116.00

Brokerage firm Baird Maintains its rating on BIO-TECHNE Corp(NASDAQ:TECH). In a research note issued to the investors, the brokerage major Raises the price-target to $116.00 per share. The shares have been rated Outperform. The rating by Baird was issued on Aug 18, 2016.

BIO-TECHNE Corp (TECH) made into the market gainers list on Mondays trading session with the shares advancing 0.33% or 0.35 points. Due to strong positive momentum, the stock ended at $106.03, which is also near the day’s high of $106.75. The stock began the session at $106.05 and the volume stood at 1,25,863 shares. The 52-week high of the shares is $117.42 and the 52 week low is $79.95. The company has a current market capitalization of $3,946 M and it has 3,72,13,571 shares in outstanding.

BIO-TECHNE Corp(TECH) last announced its earnings results on Aug 17, 2016 for Fiscal Year 2016 and Q4.Company reported revenue of $134.76M. Analysts had an estimated revenue of $129.23M. Earnings per share were $0.92. Analysts had estimated an EPS of $0.96.

Several Insider Transactions has been reported to the SEC. On Apr 22, 2016, Roger C Lucas (director) sold 100 shares at $92.40 per share price.Also, On Jun 9, 2015, Randolph C Steer (director) sold 1,000 shares at $99.39 per share price.On Feb 20, 2015, Howard V Oconnell (director) sold 5,000 shares at $95.78 per share price, according to the Form-4 filing with the securities and exchange commission.

Bio-Techne Corporation (Bio-Techne) formerly Techne Corporation develops manufactures and sells biotechnology reagents instruments and clinical diagnostic products around the world. The Company has three business segments: the Biotechnology Clinical Controls and Protein Platforms divisions. The Biotechnology segment develops manufactures and sells biotechnology research and diagnostic products around the world. The Clinical Controls segment develops and manufactures controls and calibrators for the global clinical market. The Protein Platforms segment develops and commercializes systems and consumables for protein analysis. Bio-Techne is engaged in providing specialized proteins including cytokines and growth factors antibodies related immunoassays biologically active small molecules and other reagents to the research diagnostics and clinical controls markets.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

BIO-TECHNE Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on BIO-TECHNE Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.